financetom
Business
financetom
/
Business
/
Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
Aug 15, 2025 2:55 PM

Aug 15 (Reuters) - Novo Nordisk said on

Friday the U.S. Food and Drug Administration had granted

accelerated approval for its weight-loss drug Wegovy to treat a

serious liver condition known as metabolic

dysfunction-associated steatohepatitis.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by

Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved